US SEC Filing Intelligence

VA Healthcare & Services Contracts — May 13, 2026

The Department of Veterans Affairs awarded Booz Allen Hamilton Inc. a single $809,754,946 delivery order for IT operations and services transformation, representing 100% civilian exposure with 0/1 defense-related contracts. This fully committed time-and-materials contract under full and open competition provides high funding certainty through 2025-01-22, with $317,898,571 already outlayed and steady annual revenue estimated at $140-145 million. The dominant agency theme is VA healthcare IT services modernization via NAICS 541512 and PSC D318. Highest-conviction bullish signal is Booz Allen's stable multi-year VA revenue stream amid low pricing risk. Key watch item: progress on remaining ~$492 million outlays and any modifications to the 2025-01-22 end date amid uncertain pacing.

1 total filings

Contract Deobligations Alert — May 13, 2026

This Contract Deobligations Alert synthesizes $4,176,750,195 in total civilian contract obligations across 6 awards from May 13, 2026, with 0/6 defense-related and average signal strength of 5.5/10, dominated by DHS ($1.72B), HHS ($1.57B across Bavarian Nordic A/S and Albert B. Sabin Vaccine Institute), and VA ($810M). Highest-conviction bullish signals (7/10 strength, 8/10 materiality) highlight durable revenue potential for Southwest Valley Constructors Co ($1.72B DHS), Bavarian Nordic A/S ($1.26B HHS), and Booz Allen Hamilton Inc ($809.8M VA IT services). Neutral signals temper smaller HHS R&D awards to Albert B. Sabin Vaccine Institute ($310M total) and USAID remediation to Nelson Environmental Remediation USA Ltd ($72.6M). Key risk: monitor outlay progress on multi-year contracts like Booz Allen's remaining $492M unoutlayed on VA order and Nelson's high firm-fixed-price execution risk.

6 total filings

3 high priority 4 medium 7 total filings

S&P 500 Energy Sector SEC Filings — May 13, 2026

Across the 7 filings in the USA S&P 500 Energy intelligence stream, only Devon Energy provides direct sector exposure via its $475M stake in Waterbridge Infrastructure, signaling conviction in energy infrastructure amid neutral institutional 13F snapshots from managers favoring tech and industrials. Period-over-period trends in 10-Q filers reveal volatility: KAANAPALI LAND exploded with +4,529% YoY revenue to $20.4k from property sales, Winchester Bancorp posted +44% YoY net interest income and +11.4% assets, while Hughes Satellite saw -11.2% revenue but narrowed losses dramatically. Mixed sentiments dominate (3/4 applicable), with no insider trading activity disclosed, limited capital allocation (e.g., KAANAPALI's $981 distribution), and no forward-looking guidance except Hughes' going concern warning. Portfolio-level patterns show institutions maintaining diversified, tech-heavy positions with no major shifts QoQ/YOY. Key implication: Sparse direct energy insights, but Devon's outsized Waterbridge holding flags infrastructure opportunity; monitor non-energy filers for broader market spillovers into energy via capital flows. Overall, bullish turnarounds in KAANAPALI/Winchester contrast Hughes' distress, urging selective positioning.

3 high priority 3 total filings

US SEC Trading Suspension Halt Orders — May 13, 2026

Three Nasdaq Capital Market small-cap companies disclosed critical listing compliance failures in 8-K filings around May 13, 2026, signaling heightened delisting risks amid governance lapses and share price weakness. CEA Industries violated Rule 5620(a) by failing to hold an annual shareholders' meeting within 12 months of FYE April 30, 2026, with a 45-day compliance plan deadline to June 22 and potential 180-day extension to October 27. Intrusion Inc. breached Rule 5550(a)(2) with closing bid prices below $1.00 for 30 consecutive trading days from March 25 to May 6, 2026, entering a 180-day grace period to November 3 with possible further extension via reverse split plan. Reviva Pharmaceuticals faces immediate delisting after missing its final bid price compliance deadline on May 11, with trading suspension at Nasdaq open on May 14, 2026, and shift to OTCQB under RVPH. Overarching themes include persistent QoQ share price declines (e.g., 30-day streak below $1), governance deterioration, and negative sentiment (all filings scored negative, avg materiality 9.3/10), with no bullish period-over-period trends evident. Portfolio-level implications: Increased volatility, liquidity evaporation, and short opportunities in Nasdaq small caps; no insider activity, capital allocation, or financial ratio improvements noted across filings.

41 high priority 41 total filings

US Corporate Board Director Changes SEC Filings — May 13, 2026

Across 41 SEC filings on USA Board Room Changes from May 13, 2026, the dominant theme is high C-suite and board turnover, with 12 CEO/CFO/president departures or transitions (e.g., HF Sinclair CFO termination, Power Solutions CEO resignation, Rent the Runway CEO step-down) amid neutral-to-negative sentiment, signaling potential instability in energy, pharma, and tech sectors. Annual shareholder meetings (15 filings) overwhelmingly passed director elections, auditor ratifications, and equity plans with 90-99% support (e.g., Vertex 94-99%, MDU >90%), reinforcing governance stability. Period-over-period trends show mixed financials: revenue growth in Doximity (+13% FY2026 YoY to $644.9M) and cash runway extensions (Tango to 2028, Zenas to Q2 2029), but margin compression in consumer names (Jack in the Box Restaurant-Level Margin -320 bps YoY to 16.4%) and widening losses in biopharma (Tango net loss +14% to $45.5M, Zenas +141% to $81M). Capital allocation leans bullish with Hanover's $700M buyback authorization (+$637M vs prior remainder), Coeur Mining's inaugural $0.02/share dividend, and LTIP expansions (e.g., MDU +6.56M shares). Forward-looking catalysts cluster in pharma (e.g., Zenas BLA Q2 2026, Tango data readouts 2026), while leadership promotions signal continuity (e.g., Toll Brothers EVP to President). Portfolio implication: Favor stable boards with buybacks/dividends; avoid high-turnover firms until interim stability proven.

Big Pharma Approvals — May 12, 2026

The FDA approval period from May 12 to May 12, 2026, featured 0 NMEs, 0 biosimilars, 0 label expansions, and 1 other approval, representing a quiet week dominated by a single bullish signal from Big Pharma. GENENTECH INC secured a label expansion for OCRELIZUMAB (OCREVUS), categorized as a fallback/other approval, signaling moderate upside potential (strength 5/10, materiality 5/10) for the sponsor's established franchise. No dominant therapeutic area theme emerged from this single event. The highest-conviction signal is GENENTECH INC's OCRELIZUMAB label expansion, which could support sustained revenue contribution amid limited disclosure on peak sales, exclusivity, or pricing. A key risk/watch item is the lack of disclosed commercial details, warranting monitoring for post-approval uptake and competitive dynamics.

1 total filings

7 high priority 43 medium 50 total filings

S&P 500 Industrials Sector SEC Filings — May 12, 2026

The 50 filings for USA S&P 500 Industrials stream are dominated by 37 neutral 13F-HR disclosures from global managers (US, Hong Kong, Australia, Singapore), revealing Q1 2026 portfolios heavily concentrated in tech mega-caps (Apple, MSFT, NVDA topping 80% of filings, e.g., Circle Wealth 43% AAPL) and broad ETFs, signaling sustained institutional conviction in growth equities amid diversified risk via treasuries/quality factors. Operational filings (13 total) show mixed but resilient industrials trends: Ducommun (aerospace/defense) posted record Q1 revenue +9% YoY to $209M with gross margins +70bps to 26.9% and adj EBITDA +19%; Venture Global (LNG/infra) surged revenue +59% YoY to $4.6B, raising FY26 EBITDA guidance to $8.2-8.5B with new $8.6B project financing. Contrasts include sharp declines (VenHub revenue -86% YoY, Next Bridge -11% YoY with no reserves/employees) and ongoing losses (Verde Clean Fuels improved net loss to $2.4M YoY but cash burn persists; BCSF NII -8% QoQ, NAV -2.2%). Capital allocation leans supportive (BCSF $0.42 dividend covered, Venture $0.02/share, issuances for growth), with catalysts like S&P Global Mobility Investor Day (May 12, 2026) and leadership positives (Diodes new Chair). No insider transactions reported across filings; sector portfolio-level trends highlight aero/defense outperformance vs. energy explorers' weakness, positioning industrials for infra/LNG tailwinds but destocking risks.

12 high priority 38 medium 50 total filings

S&P 500 Consumer Discretionary Sector SEC Filings — May 12, 2026

The May 12, 2026, filings for S&P 500 Consumer Discretionary reveal heavy institutional conviction via 40+ 13F-HRs, with Amazon.com as a top holding across 12 portfolios (e.g., 17.9%/$134M at GCQ Funds, $999M at Mitsubishi UFJ, $306M at United Super), alongside Uber (14%/$105M at GCQ) and exposure to eBay peers, signaling sustained allocation to e-commerce and ride-sharing amid neutral sentiment. Operational highlights include Aramark's robust Q2 FY2026 results (+15% YoY revenue to $4.9B, +12% organic, +40% adj EPS to $0.49, +116% FCF), eBay's rejection of GameStop's non-binding $20B debt-financed bid citing $80B 2025 GMV standalone strength, and mixed hospitality metrics like Ashford Hospitality's hotel sale improving pro forma net loss -4% YoY and SmartStop Self Storage's occupancy dip -70bps YoY to 92.3%. Period trends show growth divergence: 15-115% YoY revenue surges in services/infra (Aramark, JFB Construction, Cardinal Infrastructure) vs declines in volumes/occupancy (-11% rev at Next Bridge, rates down at SmartStop). Forward guidance is optimistic (e.g., Figure's Q2 vol $3.8-4.1B, Cardinal FY rev raised to $675-685M, Aramark leverage <3x FYE), with capital returns via Aramark's $25M buyback/$55M debt paydown/$0.12 dividend and Sound Financial's dividend hike to $0.21/share. Executive risks emerge (HF Sinclair CEO separation $4.7M severance, CFO leave), but no broad insider selling; overall, bullish flows favor selective e-comm/services overweight with hospitality watch.

12 high priority 12 total filings

US Executive Compensation Proxy SEC Filings — May 12, 2026

Across 12 DEF 14A filings dated May 12, 2026, a dominant theme is clustered June 2026 shareholder meetings (10/12 between June 2-25) for director elections (11/12), auditor ratifications (9/12), say-on-pay votes (4/12), and advisory agreement approvals amid control changes or M&A (5/12 funds/ETFs). Period-over-period trends reveal stark contrasts: NVIDIA's explosive FY2026 revenue +65% YoY to $215.9B and EPS +67% to $4.90 outpace peers, while CarMax EPS plunged -47.7% YoY to $1.68 amid sales declines and impairments, Apogee sales edged +3% YoY but op margin contracted -270 bps to 6.0%, and funds show no financial declines but advisor disruptions. Mixed sentiment prevails (4/12 mixed), with high materiality in growth outliers (NVIDIA, CarMax 9/10) and fund transitions (MFS, Tavia 9/10). No insider trading or capital allocation shifts noted across filings, but director ownership at Dyadic (20.9%) signals alignment. Market implications include governance catalysts for volatility, potential continuity post-approvals boosting stability in funds/tech, and relative outperformance opportunities in high-growth names like NVDA versus cyclical decliners like KMX/APOG. Portfolio-level pattern: Margin compression in 3/4 detailed financials (avg -150 bps) despite uneven revenue growth, highlighting cost pressures amid transitions.

3 high priority 3 total filings

US SEC Trading Suspension Halt Orders — May 12, 2026

Three small-cap companies—Maison Solutions Inc., Beauty Health Co (SKIN), and BIO-Key International Inc (BKYI)—disclosed Nasdaq listing non-compliance notices in 8-K filings dated around May 6-12, 2026, signaling acute regulatory distress in the USA Trading Suspensions stream. Overarching themes include governance failures (annual meeting), reporting delays (late 10-K), and market price deficiencies (bid < $1), with all exhibiting negative sentiment and high materiality (9-10/10). No enriched period-over-period financial trends (YoY/QoQ revenue, margins) were detailed, but late filings and low bids imply operational deterioration and potential QoQ bid price declines exceeding 10 consecutive days for BKYI. Critical developments: imminent trading suspension for BKYI on May 13, 2026, with delisting to OTC, while others seek compliance plans; portfolio-level pattern shows 3/3 firms at delisting risk, eroding liquidity and shareholder value. Market implications: heightened volatility, short opportunities pre-suspension, and avoidance for long portfolios amid absent positive insider activity or capital returns data.

36 high priority 36 total filings

US Corporate Distress Financial Stress SEC Filings — May 12, 2026

Across 36 filings in the USA Corporate Distress & Bankruptcy stream, key themes include Nasdaq listing non-compliance and imminent delistings in small caps (4/36 filings: Maison Solutions, Beauty Health, BIO-Key, with suspensions starting May 13, 2026), heavy reliance on dilutive equity/debt conversions and warrant issuances (6/36: Functional Brands, Securetech, Firefly, Perfect Moment, XCF Global), and ongoing debt forbearances signaling liquidity strains (Vivakor with $11.9M outstanding). Counterbalancing positives dominate larger caps with debt refinancings at lower rates (e.g., Sezzle -290bps spread, Procaccianti to 6.50%, Cinemark -0.25%, DHI extension to 2029), asset sales for non-dilutive cash (MacroGenics $122.5M), and M&A/debt-to-equity swaps (Diversified $1.175B acquisition, NSTS $73.7M buyout). Period-over-period trends limited but notable: OptimizeRx Q1 rev -10% YoY to $19.8M but adj EBITDA +120% to $3.3M, cash -14% QoQ to $20.2M; American Woodmark plant closure for $7.5M annual savings but $36-40M charges. No outright bankruptcies, but 11/36 exhibit clear distress signals vs 15 positive financings, indicating micro-cap vulnerability amid proactive deleveraging in mid/large caps. Forward catalysts cluster in Q2-Q3 2026 (compliance plans by late June, deal closes Q3), with portfolio-level margin trends unavailable but dilution risks elevated in 20% of filings.

12 high priority 12 total filings

US Merger & Acquisition SEC Filings — May 12, 2026

The 12 filings reveal a surge in US M&A and divestiture activity, with 7/12 involving asset sales, acquisitions, or JVs totaling over $5B in value, including Plains' $3.3B Canadian NGL divestiture and Collegium's $650M AZSTARYS buyout, signaling portfolio optimization and strategic refocusing amid mixed economic signals. Period-over-period trends show revenue declines in divestitures (e.g., Ashford -0.6% pro forma YoY to $1.1B) offset by loss improvements (Ashford net loss -4% to $181M, Mereo Q1 loss -48% YoY to $6.7M), while guidance upgrades (Collegium +8% revenue to $865-895M) highlight accretive deals. SPACs dominate extensions (4/5 filings), buying time for deals with neutral-to-positive sentiment. Energy midstream firms like Plains target 3.25-3.75x leverage post-sale for durable FCF, contrasting pharma's mixed clinical outcomes (Mereo Phase 3 misses primary but hits secondary endpoints). Overall, bullish on deleveraging and growth via M&A, but watch SPAC liquidity risks and clinical/regulatory hurdles; portfolio-level theme is crude oil focus and ADHD pharma expansion.

May 12, 2026 · monthly

US Pre-Market SEC Filings Roundup — May 12, 2026

Overnight SEC filings for May 11-12, 2026, are dominated by 37 13F-HR reports revealing strong institutional conviction in mega-cap tech (Apple, NVIDIA, Amazon topping 20+ portfolios, avg 20-40% allocation), signaling sustained bullishness on AI/semiconductors amid no reported changes from Q1 2026. Earnings releases show mixed Q1 2026 results: 5/7 reporting companies achieved revenue growth averaging +11% YoY (Ducommun +9%, Qnity +18%, Green Dot +17%), but margins varied (+70bps Ducommun to compressions elsewhere) and losses widened in high-growth names like BETA (+5.6% rev but -56% net income YoY). Guidance trends positive with raises (Qnity FY sales $5.225-5.375B, Optex FY rev $43-45M up from $41.3M), offset by widened loss outlooks (BETA Adj EBITDA -$355-445M). Capital raises prominent (IREN $2.6B notes due 2033, UGI €300M notes), exec transitions neutral-to-positive (Diodes new Chair, Astrana CMO resignation), and risks in compliance (Maison Nasdaq violation). Sector themes highlight aero/defense resilience, electronics outperformance, and heavy foreign investor tech bets; actionable now: buy electronic/aero dips pre-catalysts, monitor tech overweight for rotation risks.

6 high priority 44 medium 50 total filings

New Drug Approvals (Original) — May 11, 2026

The May 11, 2026 period saw 1 FDA approval categorized as Other (0 NMEs, 0 biosimilars, 0 label expansions), consisting solely of ZHEJIANG NOVUS's VORICONAZOLE biosimilar approval with a neutral signal (strength 5/10, materiality 5/10). No dominant therapeutic area theme emerges from this single approval. The highest-conviction signal is the neutral commercial implication for ZHEJIANG NOVUS's entry into the VORICONAZOLE market, representing a fallback approval with no disclosed peak sales, exclusivity, or pricing data. This dual-edged event is bullish for the new entrant ZHEJIANG NOVUS but bearish for the VORICONAZOLE originator due to potential revenue erosion. Key risk/watch item is competitive pressure on the originator's market position post-launch.

1 total filings

11 high priority 39 medium 50 total filings

S&P 500 Consumer Staples Sector SEC Filings — May 11, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (though spanning broader sectors like energy, biotech, and finance), mixed sentiment prevails with 12/20 high-materiality operational filings showing revenue growth (avg +35% YoY where positive, e.g., CleanCore +113%, Kodiak +6.2%) offset by widespread net losses or margin compression (e.g., HAIN -13% sales, OPAL -14% rev). Period-over-period trends reveal portfolio-level margin deterioration averaging -100bps in 6/10 reporting firms amid rising G&A (e.g., CleanCore +1350% YoY) and impairments, but capital allocation shines with debt reductions (ARKO -50% total debt QoQ, HAIN -$155M), buybacks/tenders (FS KKR $450M program), and reaffirmed/raised guidance (Kodiak EBITDA to $820-860M). Biotech and energy outliers like MoonLake/Intellia (BLA catalysts H2 2026) and Constellation (+1247% NI YoY) signal resilience, while 25+ 13F-HRs indicate steady institutional conviction in tech/ETFs (e.g., Apple, NVIDIA top holdings). Key implications: Favor debt deleveragers and guidance raisers for near-term alpha; monitor liquidation risks (Elme) and crypto volatility (CleanCore -$107M digital loss). Overarching theme: Defensive staples under pressure, but M&A/capex in adjacents (Calpine acquisition) drives upside.

29 high priority 21 medium 50 total filings

US SEC Filings Daily Market Digest — May 11, 2026

Across 50 SEC filings for May 11, 2026, a dominant theme is mixed financial performance with robust revenue growth in energy services (e.g., NESR +33.5% YoY, Kodiak +6.2% YoY) contrasting weakness in media/advertising (Townsquare -1.9% YoY) and select tech/consumer segments, amid 11.6% YoY revenue gains at Dole but EBITDA declines. Period-over-period trends show 18/25 quarterly reporters with YoY revenue growth averaging +25% in energy/oil vs. -5% in media, though margins compressed in 12 companies (avg -100 bps) due to impairments/expenses; net income swings positive in 10 firms via tax benefits or cost controls. Capital allocation leans shareholder-friendly with dividends/buybacks in 9 firms (e.g., NESR $0.10/share dividend + $50M repurchase), while forward-looking guidance raised in 5 (Kodiak EBITDA to $820-860M, Seadrill revenues $1.43-1.48B). Institutional 13Fs reveal concentrated bets on STAA, LU, API; IPO/SPAC momentum with EagleRock's Permian surge (308% YoY rev) and Shreya's $100M pricing signals M&A/expansion alpha. Portfolio-level, energy outperforms (avg +40% YoY EBITDA in 4 firms) vs. BDCs/REITs lagging; watch Q2 catalysts like NESR dividends and Kodiak power capacity adds for rotational trades.

11 high priority 39 medium 50 total filings

S&P 500 Healthcare Sector SEC Filings — May 11, 2026

Across 50 filings in the S&P 500 Healthcare stream, 13F-HR reports dominate (over 60%), revealing institutional portfolios overwhelmingly tilted to tech megacaps (Apple, MSFT, NVDA topping 25+ filers, e.g., $709M Apple in Cincinnati Financial) with secondary but stable healthcare exposure (AbbVie $270B Citigroup, $305M Cincinnati Insurance, Lilly $7M CIGNA). Healthcare-specific filings highlight biotech momentum with positive clinical data (Inhibrx Phase 2 ORR 44% vs 21% control +24% edge, MBX Biosciences 7% weight loss Phase 1) contrasting small-cap deterioration (Elicio Q1 loss widened to $11.8M +5% YoY, BioScience rev -38.8% YoY to $0.75M). Adjacent financials show resilient NII growth averaging +12% YoY (Esquire +23%, C&F +11%, Flushing swing to $5.8M profit) amid rising provisions (+20-100%). Capital allocation leans shareholder-friendly (Ellington monthly $0.13 dividend June 30, News Corp $1B buyback ongoing, Flushing dividend doubled to $0.44), but dilution risks loom (ACRES ~105% share issuance vote). Forward catalysts cluster Q3-Q4 2026 (Inhibrx Phase 3/PFS, MBX 12-wk data); neutral-to-mixed sentiment prevails with no notable insider trading patterns. Portfolio implication: tactical biotech alpha amid broad market tech rotation, monitor dilution votes.

14 high priority 14 total filings

US Executive Compensation Proxy SEC Filings — May 11, 2026

Across 14 DEF 14A proxy statements dated around May 11, 2026, overarching themes include routine director elections, say-on-pay advisory votes, and auditor ratifications, but with standout strategic actions: significant dilution from ACRES' internalization merger (105% dilution via 7.5M new shares), Coursera's Udemy merger boosting scale to $1.5B revenue, Jushi's domestication to Nevada, and reverse consolidations in OFA (1:10) and Revelation (up to 1:250). Period-over-period data is sparse but reveals Coursera's robust 9% YoY revenue growth to $757.5M and record $78.5M FCF, contrasting OFA's executive comp surges (CEO +1,865% YoY to $724K, CTO +483% to $215K) as the sole quantified pay trend amid multi-year comp tables in DBV, Navitas, Pulse, and others showing no declines noted. No insider trading activity reported across filings, but high insider voting control in OFA (98.68%) raises governance flags. Forward-looking catalysts cluster in June 2026 annual meetings (June 3-DBV to June 25-Navitas/Blue Dolphin), potentially impacting share structures and governance. Portfolio-level patterns show neutral sentiment dominating (10/14), with positive outliers in growth/edtech (Coursera, OFA) and mixed risks in realty/biotech dilution plays; implications favor monitoring vote outcomes for near-term volatility in small-caps.